Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CLDN18.2-positive Gastric Adenocarcinoma”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Large-scale testing (Phase 3)Looking for participantsNCT07584135
What this trial is testing

JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
NingBo Junyan Hongshi Biosciences Co., Ltd 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Early research (Phase 1)Study completedNCT01671774
What this trial is testing

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Gastric AdenocarcinomaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of Esophagus
Astellas Pharma Global Development, Inc. 29
Early research (Phase 1)Ended earlyNCT04260191
What this trial is testing

Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric and Gastroesophageal Junction Adenocarcinoma
Amgen 15
Testing effectiveness (Phase 2)Looking for participantsNCT07432295
What this trial is testing

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Who this might be right for
Solid TumorAdvanced CancerMetastatic Cancer+3 more
I-Mab Biopharma US Limited 180
Testing effectiveness (Phase 2)Looking for participantsNCT06962137
What this trial is testing

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma MetastaticGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Universitaire Ziekenhuizen KU Leuven 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795346
What this trial is testing

ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited 380
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Large-scale testing (Phase 3)Looking for participantsNCT07103668
What this trial is testing

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Who this might be right for
Gastric Adenocarcinoma
Suzhou Immunofoco Biotechnology Co., Ltd 150
Testing effectiveness (Phase 2)Looking for participantsNCT07569068
What this trial is testing

Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 88
Testing effectiveness (Phase 2)Ended earlyNCT04683939
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Who this might be right for
Solid TumorGastric CancerGastroesophageal Junction Adenocarcinoma+5 more
BioNTech SE 13
Early research (Phase 1)Study completedNCT04400383
What this trial is testing

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Solid TumorGastric CancerPancreatic Adenocarcinoma
CARsgen Therapeutics Co., Ltd. 62
Testing effectiveness (Phase 2)Looking for participantsNCT06587425
What this trial is testing

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 50
Early research (Phase 1)UnknownNCT05472857
What this trial is testing

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Who this might be right for
Gastric CancerPancreatic CancerAdvanced Ovarian Carcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07716449
What this trial is testing

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 560
Testing effectiveness (Phase 2)Study completedNCT01630083
What this trial is testing

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusCLDN18.2-positive Gastric Adenocarcinoma
Astellas Pharma Global Development, Inc. 252
Large-scale testing (Phase 3)Looking for participantsNCT07284134
What this trial is testing

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd. 560
Very early researchLooking for participantsNCT07595237
What this trial is testing

A IIT Study of 177Lu-DOTA-SNA040

Who this might be right for
Advanced Solid Tumors (Such as Gastric Cancer)Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)Advanced Solid Tumors (Such as Pancreatic Cancer)+1 more
SmartNuclide Biopharma 12
Testing effectiveness (Phase 2)Looking for participantsNCT07483567
What this trial is testing

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
CLDN18.2 PositivePrimary Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 90
Testing effectiveness (Phase 2)Looking for participantsNCT07556640
What this trial is testing

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Who this might be right for
Gastric Cancer Stage IVPeritoneal Metastases From Gastric CancerGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital 74
Next Page